Real-World Evidence of Omalizumab (Xolair) to Omlyclo (CT-P39) Switching in Chronic Idiopathic Urticaria (CIU) Patients: A Feasibility and Effectiveness Study

This project will explore whether switching patients with chronic hives (also called chronic spontaneous urticaria) from a trusted medication called Xolair® to a newer, more affordable version called Omlyclo (a biosimilar of omalizumab) is safe and effective. Xolair has helped many people manage severe symptoms like daily itching, hives, and swelling. However, because it can be costly, some patients face barriers to starting or continuing treatment long-term.

With Health Canada’s recent approval of Omlyclo, a biosimilar version of Xolair, we now have the opportunity to study how well it works in real-world clinics. This project will follow patients who choose to make the switch, tracking their symptoms and experiences over time.

The study will take place in dermatology and allergy clinics at the McGill University Health Centre, with support from a graduate student who will help collect and analyze the data. The findings will support patients and healthcare providers in making informed treatment decisions and may improve access to care across Canada by supporting the responsible use of biosimilars.

Faculty Supervisor:

Elena Netchiporouk

Student:

Partner:

Celltrion Healthcare

Discipline:

Life Sciences

Sector:

Manufacturing

University:

Research Institute of the McGill University Health Centre

Program: